Johnson & Johnson (JNJ)
| Market Cap | 426.76B |
| Revenue (ttm) | 90.63B |
| Net Income (ttm) | 22.66B |
| Shares Out | 2.41B |
| EPS (ttm) | 9.33 |
| PE Ratio | 18.98 |
| Forward PE | 16.26 |
| Dividend | $5.20 (2.95%) |
| Ex-Dividend Date | Aug 26, 2025 |
| Volume | 6,713,888 |
| Open | 176.71 |
| Previous Close | 176.46 |
| Day's Range | 176.59 - 178.51 |
| 52-Week Range | 140.68 - 181.16 |
| Beta | 0.39 |
| Analysts | Buy |
| Price Target | 178.00 (+0.45%) |
| Earnings Date | Oct 14, 2025 |
About JNJ
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizo... [Read more]
Financial Performance
In 2024, Johnson & Johnson's revenue was $88.82 billion, an increase of 4.30% compared to the previous year's $85.16 billion. Earnings were $14.07 billion, a decrease of -59.99%.
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for JNJ stock is "Buy." The 12-month stock price target is $178.0, which is an increase of 0.45% from the latest price.
News
J&J's experimental psoriasis drug shows promise against Bristol's treatment
Johnson & Johnson said on Wednesday its experimental psoriasis drug has shown superior skin clearance compared to Bristol Myers Squibb's Sotyktu in two late-stage head-to-head trials.
Icotrokinra shows superiority to deucravacitinib in first reported head-to-head trials reinforcing promise of novel targeted oral peptide for treatment of plaque psoriasis
Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo in Phase 3 ICONIC-ADVANCE studies Icotrokinra also showed sus...
Josh Brown's Best Stocks in the Market: Johnson & Johnson
Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's "Halftime Report" to explain why he's adding Johnson & Johnson to his "best stocks in the market"
Johnson & Johnson to showcase industry-leading neuropsychiatry innovations at the 2025 Psych Congress Annual Meeting
21 abstracts from across the Company's portfolio highlight clinical and real-world data on major depressive disorder, treatment-resistant depression and schizophrenia New Phase 3 data demonstrate the ...
COVID vaccine makers' shares fall as Trump officials to link shots to child deaths, report says
Shares of companies that make COVID vaccines sank Friday, after a report raised fears that Trump administration health officials will blame the vaccines for some child deaths.
J&J Painting Recognized with 2026 Consumer Choice Award for Painting Contractor in Waterloo
WATERLOO, ON / ACCESS Newswire / September 12, 2025 / J&J Painting, a trusted name in residential and commercial painting services, has been recognized with the 2026 Consumer Choice Award in the Paint...
This year healthcare is the worst performing part of the market by far, says Jim Cramer
'Mad Money' host Jim Cramer revisits Johnson & Johnson's stock after a rough year for healthcare.
After a couple years in purgatory, Johnson & Johnson is now having a strong year, says Jim Cramer
'Mad Money' host Jim Cramer revisits Johnson & Johnson's stock after a rough year for healthcare.
Johnson & Johnson seeks first European Medicines Agency approval for icotrokinra aiming to transform the plaque psoriasis treatment paradigm
Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor. 1
Johnson & Johnson (JNJ) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Johnson & Johnson (NYSE:JNJ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 11:30 AM EDT Company Participants Joaquin Duato - CEO & Chairman John Reed - Executive Vice Pre...
Trump's Going After Prescription Drug Ads. What It Means for Pharmaceutical Sales.
The effort falls well short of banning the ads outright, but could dent sales.
US FDA approves J&J's bladder cancer treatment
The U.S. Food and Drug Administration has approved Johnson & Johnson's drug delivery system for patients with a type of bladder cancer, the drugmaker said on Tuesday, offering a potential alternative ...
U.S. FDA approval of INLEXZO™ (gemcitabine intravesical system) set to transform how certain bladder cancers are treated
First and only drug releasing system to provide extended local delivery of a cancer medication into the bladder, with 82 percent of patients achieving complete response without the need for reinductio...
Johnson & Johnson: JNJ Stock To $250?
Johnson & Johnson stock (NYSE: JNJ) has delivered a remarkable 24% return in 2025 even as the S&P 500 healthcare index declined 0.2%. This raises an important question: Is this outperformance grounded...
Johnson & Johnson Elects John Morikis, Retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, to its Board of Directors
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) announced today that John Morikis, retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, has been...
Johnson & Johnson to Participate in the Bernstein 2nd Annual Healthcare Forum
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the Bernstein 2nd Annual Healthcare Forum on Wednesday, September 24th, 2025. Management will participate in a Fires...
Johnson & Johnson: All-Time Highs In Sight After Raised Guidance And A Technical Breakout
I reiterate my buy rating on JNJ, supported by steady EPS growth, robust free cash flow, and an attractive valuation. Recent quarterly results beat expectations, with management raising guidance and a...
Johnson & Johnson: A Safe Hold, But Lacking Catalysts To Beat The Market
This company boasts a strong history of dividend growth, making it attractive for income-focused investors. Currently, the stock appears slightly undervalued, but a clear catalyst is needed for it to ...
Data published in The New England Journal of Medicine demonstrate RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) is re-setting survival expectations in first-line EGFR-mutated lung cancer
Chemotherapy-free combination regimen ushers in new era for first-line treatment, with overall survival projected to exceed four years, surpassing monotherapy TKI osimertinib by more than one year RAR...
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) prevents acquired resistance versus osimertinib in first-line EGFR-mutated non-small cell lung cancer
RYBREVANT® combination extends survival and significantly reduces common EGFR and MET resistance mutations seen with osimertinib-based treatment BARCELONA, Spain , Sept. 6, 2025 /PRNewswire/ -- Johnso...
September Dogs Of The Dow Unleash One Ideal 'Safer' DiviDog
Verizon stands out as the only Dow stock meeting the 'dogcatcher' ideal: annual dividends from $1K invested exceed its share price and are well-covered. Analyst forecasts suggest top Dow Dogs could de...
Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 14th to review third-quarter results. Joaq...
Johnson & Johnson (JNJ) Presents At 2025 Wells Fargo Healthcare Conference (Transcript)
Johnson & Johnson (NYSE:JNJ) 2025 Wells Fargo Healthcare Conference September 3, 2025 11:50 AM EDT Company Participants Tim Schmid - Executive VP & Worldwide Chairman of MedTech Conference Call Parti...
Global drugmakers rush to boost US presence as tariff threat looms
Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.
Johnson & Johnson Unveils Results from the VARIPURE Substudy of SECURE, a Real-World Study on VARIPULSE™ Platform, at 2025 European Society of Cardiology (ESC) Congress
VARIPURE demonstrated strong safety outcomes with no incidence of stroke and 99.7% acute effectiveness of the VARIPULSE ™ Platform in nearly 800 enrolled patientsi IRVINE, Calif. , Sept. 2, 2025 /PRNe...